Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v3-EN
Language English English
Date Updated 2024-10-03 2024-07-10
Drug Identification Number 02501554 02501554
Brand name FENTANYL CITRATE INJECTION, USP FENTANYL CITRATE INJECTION, USP
Common or Proper name FENTANYL CITRATE INJECTION, USP FENTANYL CITRATE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients FENTANYL FENTANYL
Strength(s) 50MCG 50MCG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAMUSCULAR EPIDURAL INTRAVENOUS INTRAMUSCULAR EPIDURAL
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 2 mL 2 mL
ATC code N01AH N01AH
ATC description ANESTHETICS, GENERAL ANESTHETICS, GENERAL
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2024-07-09 2024-07-09
Estimated end date 2024-10-15 2024-08-30
Actual end date 2024-10-02
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Fentanyl Citrate Injection, USP 50 mcg/mL SD Vial 2 mL effective July 9, 2024, until October 15, 2024 Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Fentanyl Citrate Injection, USP 50 mcg/mL SD Vial 2 mL effective July 9, 2024, until August 30, 2024.
Health Canada comments